Who writes GLP-1 rankings, and how to read one
Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.
Many “best GLP-1 program” lists are written by someone who makes money when you sign up: a publisher paid a commission for each new patient, or a program ranking itself against its rivals. That can be legal, but the Federal Trade Commission (FTC) sets rules for how the money has to be disclosed, and a few checks will tell you how much to trust a list.
Three kinds of ranking you will run into
A program ranks itself. Some telehealth companies publish comparison lists that include their own service. Under the FTC’s rule on reviews, a business may not misrepresent that a website it controls gives independent reviews of a category that includes its own products [1]. A list like that is not automatically wrong, but it is advertising.
A publisher is paid per sign-up. This is affiliate marketing. The FTC says the publisher should disclose the relationship clearly and conspicuously, so readers can decide how much weight to give the recommendation [2], and the closer the disclosure sits to the recommendation, the better [3]. The words “affiliate link” on their own, or a “buy now” button, may not tell people the site gets paid [4]; “paid link” right next to the link should be enough [5].
A publisher is paid by advertisers. The FTC says a site that sells ad space has nothing extra to disclose only if the ads are obvious and the ad money does not affect which products it reviews, what it says, or where and how prominently reviews appear [6]. The same logic appears elsewhere in the FTC’s guidance: a maker that links to every authorized seller and gives no preference to the ones paying referral fees does not need a disclosure [7]. The test is whether money buys position.
Why this matters for a GLP-1 list
The FTC’s basic rule is that endorsements must be honest and not misleading [8], and an ad counts as deceptive if it misleads a significant minority of people [9]. A line saying “we may earn a commission” tells you money is involved. It does not tell you whether the order of the list follows price and quality or follows which program pays more. That second question is the one to answer before you pick a program from a ranked list.
Six checks before you trust a GLP-1 ranking
- Who runs the site? If the publisher also sells GLP-1 prescriptions, treat its list as marketing.
- Is the disclosure plain and close to the links? Look for words like “paid link” or “we earn a commission”, not a vague footer.
- Is the ranking method written down? It should say what decides the order and that payment does not.
- Which price is being compared? An introductory first-month price and the price at the dose you stay on can be very different. Check when prices were last read.
- Are compounded products mixed in with FDA-approved drugs? The FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are sold [10].
- Does it rank companies the FDA has warned? In March 2026 the FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products [11].
Watch the reviews too. The FTC’s rule bans businesses from creating or selling fake reviews [12] and from paying for reviews that must say something positive or negative [13].
How GLPLens handles this
We hold ourselves to the same checks. Our affiliate disclosure lists which programs, if any, currently pay us, and our outbound buttons are marked as sponsored links. Our methodology explains the ranking: the price table is sorted by the total published cost of the first year at the starting dose, lowest first, and programs that pay us get no extra placement. We leave out compounded drugs and programs whose company has an unresolved FDA warning letter about GLP-1 products, and for every price we keep the exact sentence it came from, the page address and the date we read it, so you can open a row and check.
That method has a limit worth knowing: ranking by the starting dose can put programs in a different order than ranking by the dose you stay on. Each program’s page in all programs and prices shows its prices dose by dose, and our research-based reviews cover cancellation terms and other details a price table leaves out.
Sources
Company-Controlled Review Websites: The final rule prohibits a business from misrepresenting that a website or entity it controls provides independent reviews or opinions about a category of products or services that includes its own products or services.
ftc.gov, read Sep 27, 2026.You should disclose your relationship to the retailer clearly and conspicuously on your site, so readers can decide how much weight to give your endorsement.
ftc.gov, read Sep 27, 2026.The closer the disclosure is to your recommendation, the better.
ftc.gov, read Sep 27, 2026.Consumers might not understand that “affiliate link” means that the person placing the link is getting paid for purchases made through the link. Similarly, a “buy now” button would not be adequate.
ftc.gov, read Sep 27, 2026.“Paid link” right next to an affiliate link should be an adequate disclosure of the nature of the link.
ftc.gov, read Sep 27, 2026.If it’s obvious what are paid ads and if a marketer’s buying ad space from you doesn’t impact what products you review, what you say about them, or the placement or prominence of those reviews, there’s nothing you need to do.
ftc.gov, read Sep 27, 2026.If you provide links on your website to all authorized vendors of your products and don’t provide any benefits or preferences to the ones that pay affiliate fees, you don’t need to make any disclosures.
ftc.gov, read Sep 27, 2026.The Guides, at their core, reflect the basic truth-in-advertising principle that endorsements must be honest and not misleading.
ftc.gov, read Sep 27, 2026.Under the law, an act or practice is deceptive if it misleads “a significant minority” of consumers.
ftc.gov, read Sep 27, 2026.However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.
fda.gov, read Sep 27, 2026.For Immediate Release: March 03, 2026 The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.
fda.gov, read Sep 27, 2026.It prohibits businesses from creating or selling such reviews or testimonials.
ftc.gov, read Sep 27, 2026.The final rule prohibits businesses from providing compensation or other incentives conditioned on the writing of consumer reviews expressing a particular sentiment, either positive or negative.
ftc.gov, read Sep 27, 2026.